English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Received: December 06, 2017; Accepted: December 22, 2017; Published: December 26, 2017 MSI (Microsatellite instability) is a molecular marker of defective DNA mismatch repair that is detected in approximately 15% of sporadic colon cancers in general and 5% of metastatic colon cancers [1,2]. The early stages colon cancers with MSI-H (High) have better stage-adjusted survival rates compared with MSS tumors. Moreover, the data analyses of randomized adjuvant therapy trials have suggested that MSI-H tumors do not benefit from treatment with 5-fluorouracil. A pooled analysis of these studies, confirmed the prognostic and predictive impact of MSI status in colon cancer [3].

Immunotherapy for colon cancers: The beginning of a new story